This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In January of 2023, the FDA also approved semaglutide for the treatment of obesity in adolescents aged 12 to 17 years. The drug works by mimicking the glucagon-like peptide-1 (GLP-1) hormone which targets areas of the brain that regulate appetite and food intake. It was previously approved for type 2 diabetes in 2022 under the name Mounjaro.
Results 📊 Body mass, BMI, and fat-free mass declined during bed rest, while relative fat mass increased — body composition got much worse. Plasma insulin and triglycerides increased, while serum total and high-density lipoprotein (HDL) cholesterol decreased. Published online October 19, 2023:JP285130.
Falling into the class of obesity with a BMI of greater than 30 makes this more likely, but so also does having excess visceral fat deposition with significant metabolic consequences at a BMI less than 30. The distinction here is the metabolic consequences of excess fat causing a health risk rather than focusing on the BMI cutoff.
A healthy lifestyle, in this instance, is defined by a combination of: BMI Nutrition Smoking Status Activity Levels Blood Pressure Diabetes Status Cholesterol Levels All of which are highly modifiable. 2023 Sep 15:e14093. Atherosclerosis. 2017 Jan;256:47-52. Eur J Clin Invest.
Clinically, about 1/3 of adults have metabolic syndrome — a cluster of conditions including abdominal obesity, high blood pressure, high blood glucose, high triglycerides, and low HDL cholesterol. Published online November 28, 2023:JP285366. The Journal of Physiology.
Clinically, about 1/3 of adults have metabolic syndrome — a cluster of conditions including abdominal obesity, high blood pressure, high blood glucose, high triglycerides, and low HDL cholesterol. Published online November 28, 2023:JP285366. The Journal of Physiology.
The app also recorded other significant heart health risk factors, such as cholesterol, weight, and physical activity via integration with external sources including electronic medical records and fitness trackers. Among participants with baseline body mass index (BMI) above 30 kg/m2, 70.4%
The 2023 Almanac results derived from the Global Burden of Disease (GBD) and spanning 1990 to 2022, were recently published in the Journal of American College of Cardiology. 2023 Dec, 82 (25) 2343–2349. The post Global Trends in Cardiovascular Diseases: Insights from the 2023 Almanac appeared first on Cardiology Update.
Share JUPITER In 2008 a landmark paper was published showing that in people without cardiovascular disease and relatively normal LDL-cholesterol (<3.4 Because of the increased risk, I am also quicker to introduce non-statin-based cholesterol-lowering agents such as ezetimibe, bempedoic acid, PCSK9 inhibitors or inclisiran when available.
Chinese Medical Journal ():10.1097/CM9.0000000000002830, October 10, 2023. Subscribe now 1 Life's Essential 8 and risk of non-communicable chronic diseases: Outcome-wide analyses.
The estimated relative risk reduction of MACE was 20% vs placebo (HR 0.80 [95% CI: 0.72, 0.90] p 1,2 The reduction of MACE with Wegovy was not impacted by age, sex, race, ethnicity, baseline BMI, or level of renal function impairment. 2023 ;389:2221-2232. World Obesity Atlas 2023. in patients randomized to Wegovy 2.4
2 Hospital in January 2022 and January 2023 and underwent PCI treatment as study subjects. MethodsWe used the convenience sampling method to select 103 patients with coronary artery disease (53 in the observation group and 50 in the control group) who were admitted to the Department of Cardiovascular Internal Medicine at the Jiaxing No.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content